Home ➤ Life Science ➤ Healthcare ➤ Biologics CDMO Market
Biologics CDMO Market
Published date: April 2025 • Formats:
Request Sample Schedule a Call

Global Biologics CDMO Market Analysis By Product Type (Monoclonal Antibodies (mAbs), Vaccines, Recombinant Proteins, Cell and Gene Therapies, Blood and Blood Components, Others), By Application (Therapeutic Applications, Diagnostic Applications, Others), By End-User (Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations (CROs), Academic and Research Institutions, Others) By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2025-2034

  • Published date: April 2025
  • Report ID: 146443
  • Number of Pages: 392
  • Format:
  • keyboard_arrow_up
    • 1. Executive Summary
      • 1.1. Definition
      • 1.2. Market Snapshot
      • 1.3. Market Overview
      • 1.4. Segment Overview
      • 1.5. Regional Overview
      • 1.6. Competitive Landscape
      • 1.7. Taxonomy
    • 2. Global Market Overview
      • 2.1. Global Market Insights and Industry Overview
      • 2.2. Market Dynamics
        • 2.2.1. Drivers
        • 2.2.2. Restraints
        • 2.2.3. Opportunities
        • 2.2.4. Key Biologics CDMO Market Trends
      • 2.3. Regulatory Framework
      • 2.4. Opportunity Map Analysis
      • 2.5. Opportunity Orbits
      • 2.6. PESTLE Analysis
      • 2.7. PORTER’S Five Force Analysis
      • 2.8. Drivers & Restraints Impact Analysis
      • 2.9. Value Chain Analysis
        • 2.9.1. List of Raw Materials Suppliers
        • 2.9.2. List of Biologics CDMO Manufacturers
        • 2.9.3. List of Dealer/Distributors
      • 2.10. Regional Market Share and BPS Analysis
      • 2.11. Impact of Macro-economic Factors/Geopolitical Factors
    • 3. Global Biologics CDMO Market Analysis and Forecast, By Segment, 2020-2034
      • 3.1. Key Findings
      • 3.2. Global Biologics CDMO Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Product Type, 2020-2034
      • 3.3. Global Biologics CDMO Market Attractiveness Analysis, By Product Type
        • 3.3.1. Monoclonal Antibodies (mAbs)
          • 3.3.1.1. Insights
          • 3.3.1.2. Key Takeaways
        • 3.3.2. Vaccines
          • 3.3.2.1. Insights
          • 3.3.2.2. Key Takeaways
        • 3.3.3. Recombinant Proteins
          • 3.3.3.1. Insights
          • 3.3.3.2. Key Takeaways
        • 3.3.4. Cell and Gene Therapies
          • 3.3.4.1. Insights
          • 3.3.4.2. Key Takeaways
        • 3.3.5. Blood and Blood Components
          • 3.3.5.1. Insights
          • 3.3.5.2. Key Takeaways
        • 3.3.6. Others
          • 3.3.6.1. Insights
          • 3.3.6.2. Key Takeaways
      • 3.4. Global Biologics CDMO Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Application, 2020-2034
      • 3.5. Global Biologics CDMO Market Attractiveness Analysis, By Application
        • 3.5.1. Therapeutic Applications
          • 3.5.1.1. Insights
          • 3.5.1.2. Key Takeaways
        • 3.5.2. Diagnostic Applications
          • 3.5.2.1. Insights
          • 3.5.2.2. Key Takeaways
        • 3.5.3. Others
          • 3.5.3.1. Insights
          • 3.5.3.2. Key Takeaways
      • 3.6. Global Biologics CDMO Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By End-User, 2020-2034
      • 3.7. Global Biologics CDMO Market Attractiveness Analysis, By End-User
        • 3.7.1. Pharmaceutical Companies
          • 3.7.1.1. Insights
          • 3.7.1.2. Key Takeaways
        • 3.7.2. Biotechnology Companies
          • 3.7.2.1. Insights
          • 3.7.2.2. Key Takeaways
        • 3.7.3. Contract Research Organizations (CROs)
          • 3.7.3.1. Insights
          • 3.7.3.2. Key Takeaways
        • 3.7.4. Academic and Research Institutions
          • 3.7.4.1. Insights
          • 3.7.4.2. Key Takeaways
        • 3.7.5. Others
          • 3.7.5.1. Insights
          • 3.7.5.2. Key Takeaways
    • 4. Global Biologics CDMO Market Analysis and Forecast, By Region, 2020-2034
      • 4.1. Key Findings
      • 4.2. Global Biologics CDMO Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Region, 2020-2034
        • 4.2.1. North America
          • 4.2.1.1. Regional Insights
        • 4.2.2. Europe
          • 4.2.2.1. Regional Insights
        • 4.2.3. Asia Pacific
          • 4.2.3.1. Regional Insights
        • 4.2.4. Latin America
          • 4.2.4.1. Regional Insights
        • 4.2.5. Middle East & Africa
          • 4.2.5.1. Regional Insights
      • 4.3. Global Biologics CDMO Market Attractiveness Analysis, By Region
    • 5. North America Biologics CDMO Market Analysis and Forecast, 2020-2034
      • 5.1. Key Findings
      • 5.2. North America Biologics CDMO Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Product Type, 2020-2034
      • 5.3. North America Biologics CDMO Market Attractiveness Analysis, By Product Type
      • 5.4. North America Biologics CDMO Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Application, 2020-2034
      • 5.5. North America Biologics CDMO Market Attractiveness Analysis, By Application
      • 5.6. North America Biologics CDMO Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By End-User, 2020-2034
      • 5.7. North America Biologics CDMO Market Attractiveness Analysis, By End-User
      • 5.8. North America Biologics CDMO Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
      • 5.9. North America Biologics CDMO Market Attractiveness Analysis, By Country
        • 5.9.1. The US
        • 5.9.2. Canada
    • 6. Europe Biologics CDMO Market Analysis and Forecast, 2020-2034
      • 6.1. Key Findings
      • 6.2. Europe Biologics CDMO Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Product Type, 2020-2034
      • 6.3. Europe Biologics CDMO Market Attractiveness Analysis, By Product Type
      • 6.4. Europe Biologics CDMO Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Application, 2020-2034
      • 6.5. Europe Biologics CDMO Market Attractiveness Analysis, By Application
      • 6.6. Europe Biologics CDMO Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By End-User, 2020-2034
      • 6.7. Europe Biologics CDMO Market Attractiveness Analysis, By End-User
      • 6.8. Europe Biologics CDMO Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
      • 6.9. Europe Biologics CDMO Market Attractiveness Analysis, By Country
        • 6.9.1. Germany
        • 6.9.2. The UK
        • 6.9.3. France
        • 6.9.4. Spain
        • 6.9.5. Italy
        • 6.9.6. Russia
        • 6.9.7. Netherland
        • 6.9.8. Rest of Europe
    • 7. Asia Pacific Biologics CDMO Market Analysis and Forecast, 2020-2034
      • 7.1. Key Findings
      • 7.2. Asia Pacific Biologics CDMO Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Product Type, 2020-2034
      • 7.3. Asia Pacific Biologics CDMO Market Attractiveness Analysis, By Product Type
      • 7.4. Asia Pacific Biologics CDMO Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Application, 2020-2034
      • 7.5. Asia Pacific Biologics CDMO Market Attractiveness Analysis, By Application
      • 7.6. Asia Pacific Biologics CDMO Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By End-User, 2020-2034
      • 7.7. Asia Pacific Biologics CDMO Market Attractiveness Analysis, By End-User
      • 7.8. Asia Pacific Biologics CDMO Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
      • 7.9. Asia Pacific Biologics CDMO Market Attractiveness Analysis, By Country
        • 7.9.1. China
        • 7.9.2. Japan
        • 7.9.3. South Korea
        • 7.9.4. India
        • 7.9.5. Australia
        • 7.9.6. New Zealand
        • 7.9.7. Singapore
        • 7.9.8. Thailand
        • 7.9.9. Vietnam
        • 7.9.10. Rest of Asia Pacific
    • 8. Latin America Biologics CDMO Market Analysis and Forecast, 2020-2034
      • 8.1. Key Findings
      • 8.2. Latin America Biologics CDMO Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Product Type, 2020-2034
      • 8.3. Latin America Biologics CDMO Market Attractiveness Analysis, By Product Type
      • 8.4. Latin America Biologics CDMO Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Application, 2020-2034
      • 8.5. Latin America Biologics CDMO Market Attractiveness Analysis, By Application
      • 8.6. Latin America Biologics CDMO Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By End-User, 2020-2034
      • 8.7. Latin America Biologics CDMO Market Attractiveness Analysis, By End-User
      • 8.8. Latin America Biologics CDMO Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
      • 8.9. Latin America Biologics CDMO Market Attractiveness Analysis, By Country
        • 8.9.1. Brazil
        • 8.9.2. Mexico
        • 8.9.3. Rest of Latin America
    • 9. Middle East & Africa Biologics CDMO Market Analysis and Forecast, 2020-2034
      • 9.1. Key Findings
      • 9.2. Middle East & Africa Biologics CDMO Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Product Type, 2020-2034
      • 9.3. Middle East & Africa Biologics CDMO Market Attractiveness Analysis, By Product Type
      • 9.4. Middle East & Africa Biologics CDMO Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Application, 2020-2034
      • 9.5. Middle East & Africa Biologics CDMO Market Attractiveness Analysis, By Application
      • 9.6. Middle East & Africa Biologics CDMO Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By End-User, 2020-2034
      • 9.7. Middle East & Africa Biologics CDMO Market Attractiveness Analysis, By End-User
      • 9.8. Middle East & Africa Biologics CDMO Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
      • 9.9. Middle East & Africa Biologics CDMO Market Attractiveness Analysis, By Country
        • 9.9.1. South Africa
        • 9.9.2. Saudi Arabia
        • 9.9.3. UAE
        • 9.9.4. Rest of Middle East & Africa
    • 10. Competitive Landscape & Company Profiles
      • 10.1. Market Competition Scenario Analysis, By Company
        • 10.1.1. Key Takeaways
      • 10.2. Overview of Major Market Players
      • 10.3. Competitor Landscape
      • 10.4. Strategic Mapping
      • 10.5. Company Life Cycle Analysis
      • 10.6. Company Market Share Analysis
      • 10.7. Company Profiles
        • 10.7.1. Lonza Group
          • 10.7.1.1. Company Details
          • 10.7.1.2. Business Overview
          • 10.7.1.3. Product Portfolio
          • 10.7.1.4. Financial Insights
          • 10.7.1.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.1.6. SWOT Analysis
          • 10.7.1.7. Geographic Footprint
        • 10.7.2. WuXi AppTec
          • 10.7.2.1. Company Details
          • 10.7.2.2. Business Overview
          • 10.7.2.3. Product Portfolio
          • 10.7.2.4. Financial Insights
          • 10.7.2.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.2.6. SWOT Analysis
          • 10.7.2.7. Geographic Footprint
        • 10.7.3. Samsung Biologics
          • 10.7.3.1. Company Details
          • 10.7.3.2. Business Overview
          • 10.7.3.3. Product Portfolio
          • 10.7.3.4. Financial Insights
          • 10.7.3.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.3.6. SWOT Analysis
          • 10.7.3.7. Geographic Footprint
        • 10.7.4. Boehringer Ingelheim
          • 10.7.4.1. Company Details
          • 10.7.4.2. Business Overview
          • 10.7.4.3. Product Portfolio
          • 10.7.4.4. Financial Insights
          • 10.7.4.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.4.6. SWOT Analysis
          • 10.7.4.7. Geographic Footprint
        • 10.7.5. Catalent
          • 10.7.5.1. Company Details
          • 10.7.5.2. Business Overview
          • 10.7.5.3. Product Portfolio
          • 10.7.5.4. Financial Insights
          • 10.7.5.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.5.6. SWOT Analysis
          • 10.7.5.7. Geographic Footprint
        • 10.7.6. Recipharm
          • 10.7.6.1. Company Details
          • 10.7.6.2. Business Overview
          • 10.7.6.3. Product Portfolio
          • 10.7.6.4. Financial Insights
          • 10.7.6.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.6.6. SWOT Analysis
          • 10.7.6.7. Geographic Footprint
        • 10.7.7. Fujifilm Diosynth Biotechnologies
          • 10.7.7.1. Company Details
          • 10.7.7.2. Business Overview
          • 10.7.7.3. Product Portfolio
          • 10.7.7.4. Financial Insights
          • 10.7.7.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.7.6. SWOT Analysis
          • 10.7.7.7. Geographic Footprint
        • 10.7.8. Vetter Pharma
          • 10.7.8.1. Company Details
          • 10.7.8.2. Business Overview
          • 10.7.8.3. Product Portfolio
          • 10.7.8.4. Financial Insights
          • 10.7.8.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.8.6. SWOT Analysis
          • 10.7.8.7. Geographic Footprint
        • 10.7.9. Rentschler Biopharma
          • 10.7.9.1. Company Details
          • 10.7.9.2. Business Overview
          • 10.7.9.3. Product Portfolio
          • 10.7.9.4. Financial Insights
          • 10.7.9.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.9.6. SWOT Analysis
          • 10.7.9.7. Geographic Footprint
        • 10.7.10. CordenPharma
          • 10.7.10.1. Company Details
          • 10.7.10.2. Business Overview
          • 10.7.10.3. Product Portfolio
          • 10.7.10.4. Financial Insights
          • 10.7.10.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.10.6. SWOT Analysis
          • 10.7.10.7. Geographic Footprint
        • 10.7.11. Minakem
          • 10.7.11.1. Company Details
          • 10.7.11.2. Business Overview
          • 10.7.11.3. Product Portfolio
          • 10.7.11.4. Financial Insights
          • 10.7.11.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.11.6. SWOT Analysis
          • 10.7.11.7. Geographic Footprint
        • 10.7.12. KBI Biopharma
          • 10.7.12.1. Company Details
          • 10.7.12.2. Business Overview
          • 10.7.12.3. Product Portfolio
          • 10.7.12.4. Financial Insights
          • 10.7.12.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
          • 10.7.12.6. SWOT Analysis
          • 10.7.12.7. Geographic Footprint
    • 11. Methodology and Data Source
      • 11.1. Methodology/Research Approach
      • 11.2. Market Size Estimation
      • 11.3. Market Breakdown and Data Triangulation
      • 11.4. Data Source
      • 11.5. Secondary Sources
      • 11.6. Primary Sources
      • 11.7. Appendix
      • 11.8. Disclaimer
    • List of Tables
      • Table 1. Global Biologics CDMO Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 2. Global Biologics CDMO Market Value (US$ Mn), By Application, 2020-2034
      • Table 3. Global Biologics CDMO Market Value (US$ Mn), By End-User, 2020-2034
      • Table 4. Global Biologics CDMO Market Value (US$ Mn), By Region, 2020-2034
      • Table 5. North America Biologics CDMO Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 6. North America Biologics CDMO Market Value (US$ Mn), By Application, 2020-2034
      • Table 7. North America Biologics CDMO Market Value (US$ Mn), By End-User, 2020-2034
      • Table 8. North America Biologics CDMO Market Value (US$ Mn), By Country, 2020-2034
      • Table 9. The US Biologics CDMO Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 10. The US Biologics CDMO Market Value (US$ Mn), By Application, 2020-2034
      • Table 11. The US Biologics CDMO Market Value (US$ Mn), By End-User, 2020-2034
      • Table 12. Canada Biologics CDMO Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 13. Canada Biologics CDMO Market Value (US$ Mn), By Application, 2020-2034
      • Table 14. Canada Biologics CDMO Market Value (US$ Mn), By End-User, 2020-2034
      • Table 15. Europe Biologics CDMO Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 16. Europe Biologics CDMO Market Value (US$ Mn), By Application, 2020-2034
      • Table 17. Europe Biologics CDMO Market Value (US$ Mn), By End-User, 2020-2034
      • Table 18. Europe Biologics CDMO Market Value (US$ Mn), By Country, 2020-2034
      • Table 19. Germany Biologics CDMO Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 20. Germany Biologics CDMO Market Value (US$ Mn), By Application, 2020-2034
      • Table 21. Germany Biologics CDMO Market Value (US$ Mn), By End-User, 2020-2034
      • Table 22. The UK Biologics CDMO Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 23. The UK Biologics CDMO Market Value (US$ Mn), By Application, 2020-2034
      • Table 24. The UK Biologics CDMO Market Value (US$ Mn), By End-User, 2020-2034
      • Table 25. France Biologics CDMO Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 26. France Biologics CDMO Market Value (US$ Mn), By Application, 2020-2034
      • Table 27. France Biologics CDMO Market Value (US$ Mn), By End-User, 2020-2034
      • Table 28. Spain Biologics CDMO Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 29. Spain Biologics CDMO Market Value (US$ Mn), By Application, 2020-2034
      • Table 30. Spain Biologics CDMO Market Value (US$ Mn), By End-User, 2020-2034
      • Table 31. Italy Biologics CDMO Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 32. Italy Biologics CDMO Market Value (US$ Mn), By Application, 2020-2034
      • Table 33. Italy Biologics CDMO Market Value (US$ Mn), By End-User, 2020-2034
      • Table 34. Russia Biologics CDMO Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 35. Russia Biologics CDMO Market Value (US$ Mn), By Application, 2020-2034
      • Table 36. Russia Biologics CDMO Market Value (US$ Mn), By End-User, 2020-2034
      • Table 37. Netherland Biologics CDMO Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 38. Netherland Biologics CDMO Market Value (US$ Mn), By Application, 2020-2034
      • Table 39. Netherland Biologics CDMO Market Value (US$ Mn), By End-User, 2020-2034
      • Table 40. Rest of Europe Biologics CDMO Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 41. Rest of Europe Biologics CDMO Market Value (US$ Mn), By Application, 2020-2034
      • Table 42. Rest of Europe Biologics CDMO Market Value (US$ Mn), By End-User, 2020-2034
      • Table 43. Asia Pacific Biologics CDMO Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 44. Asia Pacific Biologics CDMO Market Value (US$ Mn), By Application, 2020-2034
      • Table 45. Asia Pacific Biologics CDMO Market Value (US$ Mn), By End-User, 2020-2034
      • Table 46. Asia Pacific Biologics CDMO Market Value (US$ Mn), By Country, 2020-2034
      • Table 47. China Biologics CDMO Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 48. China Biologics CDMO Market Value (US$ Mn), By Application, 2020-2034
      • Table 49. China Biologics CDMO Market Value (US$ Mn), By End-User, 2020-2034
      • Table 50. India Biologics CDMO Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 51. India Biologics CDMO Market Value (US$ Mn), By Application, 2020-2034
      • Table 52. India Biologics CDMO Market Value (US$ Mn), By End-User, 2020-2034
      • Table 53. Japan Biologics CDMO Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 54. Japan Biologics CDMO Market Value (US$ Mn), By Application, 2020-2034
      • Table 55. Japan Biologics CDMO Market Value (US$ Mn), By End-User, 2020-2034
      • Table 56. South Korea Biologics CDMO Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 57. South Korea Biologics CDMO Market Value (US$ Mn), By Application, 2020-2034
      • Table 58. South Korea Biologics CDMO Market Value (US$ Mn), By End-User, 2020-2034
      • Table 59. Australia Biologics CDMO Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 60. Australia Biologics CDMO Market Value (US$ Mn), By Application, 2020-2034
      • Table 61. Australia Biologics CDMO Market Value (US$ Mn), By End-User, 2020-2034
      • Table 62. New Zealand Biologics CDMO Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 63. New Zealand Biologics CDMO Market Value (US$ Mn), By Application, 2020-2034
      • Table 64. New Zealand Biologics CDMO Market Value (US$ Mn), By End-User, 2020-2034
      • Table 65. Singapore Biologics CDMO Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 66. Singapore Biologics CDMO Market Value (US$ Mn), By Application, 2020-2034
      • Table 67. Singapore Biologics CDMO Market Value (US$ Mn), By End-User, 2020-2034
      • Table 68. Thailand Biologics CDMO Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 69. Thailand Biologics CDMO Market Value (US$ Mn), By Application, 2020-2034
      • Table 70. Thailand Biologics CDMO Market Value (US$ Mn), By End-User, 2020-2034
      • Table 71. Vietnam Biologics CDMO Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 72. Vietnam Biologics CDMO Market Value (US$ Mn), By Application, 2020-2034
      • Table 73. Vietnam Biologics CDMO Market Value (US$ Mn), By End-User, 2020-2034
      • Table 74. Rest of Asia Pacific Biologics CDMO Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 75. Rest of Asia Pacific Biologics CDMO Market Value (US$ Mn), By Application, 2020-2034
      • Table 76. Rest of Asia Pacific Biologics CDMO Market Value (US$ Mn), By End-User, 2020-2034
      • Table 77. Latin America Biologics CDMO Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 78. Latin America Biologics CDMO Market Value (US$ Mn), By Application, 2020-2034
      • Table 79. Latin America Biologics CDMO Market Value (US$ Mn), By End-User, 2020-2034
      • Table 80. Latin America Biologics CDMO Market Value (US$ Mn), By Country, 2020-2034
      • Table 81. Brazil Biologics CDMO Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 82. Brazil Biologics CDMO Market Value (US$ Mn), By Application, 2020-2034
      • Table 83. Brazil Biologics CDMO Market Value (US$ Mn), By End-User, 2020-2034
      • Table 84. Mexico Biologics CDMO Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 85. Mexico Biologics CDMO Market Value (US$ Mn), By Application, 2020-2034
      • Table 86. Mexico Biologics CDMO Market Value (US$ Mn), By End-User, 2020-2034
      • Table 87. Rest of Latin America Biologics CDMO Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 88. Rest of Latin America Biologics CDMO Market Value (US$ Mn), By Application, 2020-2034
      • Table 89. Rest of Latin America Biologics CDMO Market Value (US$ Mn), By End-User, 2020-2034
      • Table 90. Middle East & Africa Biologics CDMO Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 91. Middle East & Africa Biologics CDMO Market Value (US$ Mn), By Application, 2020-2034
      • Table 92. Middle East & Africa Biologics CDMO Market Value (US$ Mn), By End-User, 2020-2034
      • Table 93. Middle East & Africa Biologics CDMO Market Value (US$ Mn), By Country, 2020-2034
      • Table 94. South Africa Biologics CDMO Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 95. South Africa Biologics CDMO Market Value (US$ Mn), By Application, 2020-2034
      • Table 96. South Africa Biologics CDMO Market Value (US$ Mn), By End-User, 2020-2034
      • Table 97. Saudi Arabia Biologics CDMO Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 98. Saudi Arabia Biologics CDMO Market Value (US$ Mn), By Application, 2020-2034
      • Table 99. Saudi Arabia Biologics CDMO Market Value (US$ Mn), By End-User, 2020-2034
      • Table 100. UAE Biologics CDMO Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 101. UAE Biologics CDMO Market Value (US$ Mn), By Application, 2020-2034
      • Table 102. UAE Biologics CDMO Market Value (US$ Mn), By End-User, 2020-2034
      • Table 103. Rest of Middle East & Africa Biologics CDMO Market Value (US$ Mn), By Product Type, 2020-2034
      • Table 104. Rest of Middle East & Africa Biologics CDMO Market Value (US$ Mn), By Application, 2020-2034
      • Table 105. Rest of Middle East & Africa Biologics CDMO Market Value (US$ Mn), By End-User, 2020-2034
    • List of Figures
      • Figure 1. Global Biologics CDMO Market Snapshot: Market Value (US$ Mn), 2020-2034
      • Figure 2. Opportunity Map
      • Figure 3. Opportunity Orbit
      • Figure 4. Regional Market Share and BPS Analysis in Biologics CDMO Market
      • Figure 5. Global Biologics CDMO Market Analysis, By Product Type, 2020, 2024 and 2034
      • Figure 6. Global Biologics CDMO Market Attractiveness Analysis, By Product Type
      • Figure 7. Global Biologics CDMO Market Analysis, By Application, 2020, 2024 and 2034
      • Figure 8. Global Biologics CDMO Market Attractiveness Analysis, By Application
      • Figure 9. Global Biologics CDMO Market Analysis, By End-User, 2020, 2024 and 2034
      • Figure 10. Global Biologics CDMO Market Attractiveness Analysis, By End-User
      • Figure 11. Global Biologics CDMO Market Analysis, By Region, 2020, 2024 and 2034
      • Figure 12. Global Biologics CDMO Market Attractiveness Analysis, By Region
      • Figure 13. North America Biologics CDMO Market Analysis, By Product Type, 2020, 2024 and 2034
      • Figure 14. North America Biologics CDMO Market Attractiveness Analysis, By Product Type
      • Figure 15. North America Biologics CDMO Market (US$ Mn), by Monoclonal Antibodies (mAbs), 2020-2034
      • Figure 16. North America Biologics CDMO Market (US$ Mn), by Vaccines, 2020-2034
      • Figure 17. North America Biologics CDMO Market (US$ Mn), by Recombinant Proteins, 2020-2034
      • Figure 18. North America Biologics CDMO Market (US$ Mn), by Cell and Gene Therapies, 2020-2034
      • Figure 19. North America Biologics CDMO Market (US$ Mn), by Blood and Blood Components, 2020-2034
      • Figure 20. North America Biologics CDMO Market (US$ Mn), by Others, 2020-2034
      • Figure 21. North America Biologics CDMO Market Analysis, By Application, 2020, 2024 and 2034
      • Figure 22. North America Biologics CDMO Market Attractiveness Analysis, By Application
      • Figure 23. North America Biologics CDMO Market (US$ Mn), by Therapeutic Applications, 2020-2034
      • Figure 24. North America Biologics CDMO Market (US$ Mn), by Diagnostic Applications, 2020-2034
      • Figure 25. North America Biologics CDMO Market (US$ Mn), by Others, 2020-2034
      • Figure 26. North America Biologics CDMO Market Analysis, By End-User, 2020, 2024 and 2034
      • Figure 27. North America Biologics CDMO Market Attractiveness Analysis, By End-User
      • Figure 28. North America Biologics CDMO Market (US$ Mn), by Pharmaceutical Companies, 2020-2034
      • Figure 29. North America Biologics CDMO Market (US$ Mn), by Biotechnology Companies, 2020-2034
      • Figure 30. North America Biologics CDMO Market (US$ Mn), by Contract Research Organizations (CROs), 2020-2034
      • Figure 31. North America Biologics CDMO Market (US$ Mn), by Academic and Research Institutions, 2020-2034
      • Figure 32. North America Biologics CDMO Market (US$ Mn), by Others, 2020-2034
      • Figure 33. North America Biologics CDMO Market Analysis, By Country, 2020, 2024 and 2034
      • Figure 34. North America Biologics CDMO Market Attractiveness Analysis, By Country
      • Figure 35. Europe Biologics CDMO Market Analysis, By Product Type, 2020, 2024 and 2034
      • Figure 36. Europe Biologics CDMO Market Attractiveness Analysis, By Product Type
      • Figure 37. Europe Biologics CDMO Market (US$ Mn), by Monoclonal Antibodies (mAbs), 2020-2034
      • Figure 38. Europe Biologics CDMO Market (US$ Mn), by Vaccines, 2020-2034
      • Figure 39. Europe Biologics CDMO Market (US$ Mn), by Recombinant Proteins, 2020-2034
      • Figure 40. Europe Biologics CDMO Market (US$ Mn), by Cell and Gene Therapies, 2020-2034
      • Figure 41. Europe Biologics CDMO Market (US$ Mn), by Blood and Blood Components, 2020-2034
      • Figure 42. Europe Biologics CDMO Market (US$ Mn), by Others, 2020-2034
      • Figure 43. Europe Biologics CDMO Market Analysis, By Application, 2020, 2024 and 2034
      • Figure 44. Europe Biologics CDMO Market Attractiveness Analysis, By Application
      • Figure 45. Europe Biologics CDMO Market (US$ Mn), by Therapeutic Applications, 2020-2034
      • Figure 46. Europe Biologics CDMO Market (US$ Mn), by Diagnostic Applications, 2020-2034
      • Figure 47. Europe Biologics CDMO Market (US$ Mn), by Others, 2020-2034
      • Figure 48. Europe Biologics CDMO Market Analysis, By End-User, 2020, 2024 and 2034
      • Figure 49. Europe Biologics CDMO Market Attractiveness Analysis, By End-User
      • Figure 50. Europe Biologics CDMO Market (US$ Mn), by Pharmaceutical Companies, 2020-2034
      • Figure 51. Europe Biologics CDMO Market (US$ Mn), by Biotechnology Companies, 2020-2034
      • Figure 52. Europe Biologics CDMO Market (US$ Mn), by Contract Research Organizations (CROs), 2020-2034
      • Figure 53. Europe Biologics CDMO Market (US$ Mn), by Academic and Research Institutions, 2020-2034
      • Figure 54. Europe Biologics CDMO Market (US$ Mn), by Others, 2020-2034
      • Figure 55. Europe Biologics CDMO Market Analysis, By Country, 2020, 2024 and 2034
      • Figure 56. Europe Biologics CDMO Market Attractiveness Analysis, By Country
      • Figure 57. Asia Pacific Biologics CDMO Market Analysis, By Product Type, 2020, 2024 and 2034
      • Figure 58. Asia Pacific Biologics CDMO Market Attractiveness Analysis, By Product Type
      • Figure 59. Asia Pacific Biologics CDMO Market (US$ Mn), by Monoclonal Antibodies (mAbs), 2020-2034
      • Figure 60. Asia Pacific Biologics CDMO Market (US$ Mn), by Vaccines, 2020-2034
      • Figure 61. Asia Pacific Biologics CDMO Market (US$ Mn), by Recombinant Proteins, 2020-2034
      • Figure 62. Asia Pacific Biologics CDMO Market (US$ Mn), by Cell and Gene Therapies, 2020-2034
      • Figure 63. Asia Pacific Biologics CDMO Market (US$ Mn), by Blood and Blood Components, 2020-2034
      • Figure 64. Asia Pacific Biologics CDMO Market (US$ Mn), by Others, 2020-2034
      • Figure 65. Asia Pacific Biologics CDMO Market Analysis, By Application, 2020, 2024 and 2034
      • Figure 66. Asia Pacific Biologics CDMO Market Attractiveness Analysis, By Application
      • Figure 67. Asia Pacific Biologics CDMO Market (US$ Mn), by Therapeutic Applications, 2020-2034
      • Figure 68. Asia Pacific Biologics CDMO Market (US$ Mn), by Diagnostic Applications, 2020-2034
      • Figure 69. Asia Pacific Biologics CDMO Market (US$ Mn), by Others, 2020-2034
      • Figure 70. Asia Pacific Biologics CDMO Market Analysis, By End-User, 2020, 2024 and 2034
      • Figure 71. Asia Pacific Biologics CDMO Market Attractiveness Analysis, By End-User
      • Figure 72. Asia Pacific Biologics CDMO Market (US$ Mn), by Pharmaceutical Companies, 2020-2034
      • Figure 73. Asia Pacific Biologics CDMO Market (US$ Mn), by Biotechnology Companies, 2020-2034
      • Figure 74. Asia Pacific Biologics CDMO Market (US$ Mn), by Contract Research Organizations (CROs), 2020-2034
      • Figure 75. Asia Pacific Biologics CDMO Market (US$ Mn), by Academic and Research Institutions, 2020-2034
      • Figure 76. Asia Pacific Biologics CDMO Market (US$ Mn), by Others, 2020-2034
      • Figure 77. Asia Pacific Biologics CDMO Market Analysis, By Country, 2020, 2024 and 2034
      • Figure 78. Asia Pacific Biologics CDMO Market Attractiveness Analysis, By Country
      • Figure 79. Latin America Biologics CDMO Market Analysis, By Product Type, 2020, 2024 and 2034
      • Figure 80. Latin America Biologics CDMO Market Attractiveness Analysis, By Product Type
      • Figure 81. Latin America Biologics CDMO Market (US$ Mn), by Monoclonal Antibodies (mAbs), 2020-2034
      • Figure 82. Latin America Biologics CDMO Market (US$ Mn), by Vaccines, 2020-2034
      • Figure 83. Latin America Biologics CDMO Market (US$ Mn), by Recombinant Proteins, 2020-2034
      • Figure 84. Latin America Biologics CDMO Market (US$ Mn), by Cell and Gene Therapies, 2020-2034
      • Figure 85. Latin America Biologics CDMO Market (US$ Mn), by Blood and Blood Components, 2020-2034
      • Figure 86. Latin America Biologics CDMO Market (US$ Mn), by Others, 2020-2034
      • Figure 87. Latin America Biologics CDMO Market Analysis, By Application, 2020, 2024 and 2034
      • Figure 88. Latin America Biologics CDMO Market Attractiveness Analysis, By Application
      • Figure 89. Latin America Biologics CDMO Market (US$ Mn), by Therapeutic Applications, 2020-2034
      • Figure 90. Latin America Biologics CDMO Market (US$ Mn), by Diagnostic Applications, 2020-2034
      • Figure 91. Latin America Biologics CDMO Market (US$ Mn), by Others, 2020-2034
      • Figure 92. Latin America Biologics CDMO Market Analysis, By End-User, 2020, 2024 and 2034
      • Figure 93. Latin America Biologics CDMO Market Attractiveness Analysis, By End-User
      • Figure 94. Latin America Biologics CDMO Market (US$ Mn), by Pharmaceutical Companies, 2020-2034
      • Figure 95. Latin America Biologics CDMO Market (US$ Mn), by Biotechnology Companies, 2020-2034
      • Figure 96. Latin America Biologics CDMO Market (US$ Mn), by Contract Research Organizations (CROs), 2020-2034
      • Figure 97. Latin America Biologics CDMO Market (US$ Mn), by Academic and Research Institutions, 2020-2034
      • Figure 98. Latin America Biologics CDMO Market (US$ Mn), by Others, 2020-2034
      • Figure 99. Latin America Biologics CDMO Market Analysis, By Country, 2020, 2024 and 2034
      • Figure 100. Latin America Biologics CDMO Market Attractiveness Analysis, By Country
      • Figure 101. Middle East & Africa Biologics CDMO Market Analysis, By Product Type, 2020, 2024 and 2034
      • Figure 102. Middle East & Africa Biologics CDMO Market Attractiveness Analysis, By Product Type
      • Figure 103. Middle East & Africa Biologics CDMO Market (US$ Mn), by Monoclonal Antibodies (mAbs), 2020-2034
      • Figure 104. Middle East & Africa Biologics CDMO Market (US$ Mn), by Vaccines, 2020-2034
      • Figure 105. Middle East & Africa Biologics CDMO Market (US$ Mn), by Recombinant Proteins, 2020-2034
      • Figure 106. Middle East & Africa Biologics CDMO Market (US$ Mn), by Cell and Gene Therapies, 2020-2034
      • Figure 107. Middle East & Africa Biologics CDMO Market (US$ Mn), by Blood and Blood Components, 2020-2034
      • Figure 108. Middle East & Africa Biologics CDMO Market (US$ Mn), by Others, 2020-2034
      • Figure 109. Middle East & Africa Biologics CDMO Market Analysis, By Application, 2020, 2024 and 2034
      • Figure 110. Middle East & Africa Biologics CDMO Market Attractiveness Analysis, By Application
      • Figure 111. Middle East & Africa Biologics CDMO Market (US$ Mn), by Therapeutic Applications, 2020-2034
      • Figure 112. Middle East & Africa Biologics CDMO Market (US$ Mn), by Diagnostic Applications, 2020-2034
      • Figure 113. Middle East & Africa Biologics CDMO Market (US$ Mn), by Others, 2020-2034
      • Figure 114. Middle East & Africa Biologics CDMO Market Analysis, By End-User, 2020, 2024 and 2034
      • Figure 115. Middle East & Africa Biologics CDMO Market Attractiveness Analysis, By End-User
      • Figure 116. Middle East & Africa Biologics CDMO Market (US$ Mn), by Pharmaceutical Companies, 2020-2034
      • Figure 117. Middle East & Africa Biologics CDMO Market (US$ Mn), by Biotechnology Companies, 2020-2034
      • Figure 118. Middle East & Africa Biologics CDMO Market (US$ Mn), by Contract Research Organizations (CROs), 2020-2034
      • Figure 119. Middle East & Africa Biologics CDMO Market (US$ Mn), by Academic and Research Institutions, 2020-2034
      • Figure 120. Middle East & Africa Biologics CDMO Market (US$ Mn), by Others, 2020-2034
      • Figure 121. Middle East & Africa Biologics CDMO Market Analysis, By Country, 2020, 2024 and 2034
      • Figure 122. Middle East & Africa Biologics CDMO Market Attractiveness Analysis, By Country
    • Lonza Group AG Company Profile
    • WuXi AppTec
    • Samsung Biologics
    • Boehringer Ingelheim
    • Catalent
    • Recipharm
    • Fujifilm Diosynth Biotechnologies
    • Vetter Pharma
    • Rentschler Biopharma
    • CordenPharma
    • Minakem
    • KBI Biopharma
  • settingsSettings

Related Reports

Our Clients

  • Our Clients
Inquiry Before Buying

Biologics CDMO Market
  • 146443
  • April 2025
    • ★★★★★
      ★★★★★
    • (142)
add_shopping_cart Buy Now
Trusted by more than 17382 organizations globally
  • Client Logo
  • Client Logo
  • Client Logo
✖
Request a Sample Report
We'll get back to you as quickly as possible

Single User
$6,000
$3,999
USD / per unit
save 24%
Multi User
$8,000
$5,999
USD / per unit
save 28%
Corporate User
$10,000
$6,999
USD / per unit
save 32%
e-Access
Report Library Access
Data Set (Excel)
Print
Company Profile Library Access
Interactive Dashboard
Free Custumization No up to 10 hrs work up to 30 hrs work
Accessibility 1 User 2-5 User Unlimited
Analyst Support up to 20 hrs up to 40 hrs up to 50 hrs
Benefit Up to 20% off on next purchase Up to 25% off on next purchase Up to 30% off on next purchase
Buy Now ($ 3,999) Buy Now ($ 5,999) Buy Now ($ 6,999)
Find Help
Legal
Explore
Secured Payment Options
Secured Payment Options